Rahul Ballal, Imara CEO
September 9, 2022 06:42 AM EDT
Deals

Imara sells failed blood dis­or­der drug to heart dis­ease out­fit Car­du­ri­on

Lei Lei Wu

News Reporter

Af­ter whit­tling it­self down from 41 to just six em­ploy­ees fol­low­ing a fruit­less read­out on its blood dis­or­der drug ear­li­er this year, Imara has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times